EuroIntervention focus on

EXCELLA™ FIRST-IN-MAN (FIM) STUDY

A novolimus-eluting stent was implanted in a total of 15 patients. Diabetes was detected in 47% of the cohort. At 4-month angiographic followup there was in-stent late lumen loss (0.15±0.29 mm) by QCA and % volume obstruction (2.6±2.6) by IVUS. The angiographic in-stent late lumen loss results at eight months were 0.31±0.25mm and % volume obstruction by IVUS was 6.0±4.4%. Late ISA and MACE was not evidenced at 9 months.
Read more

EUROPEAN EXPERIENCE WITH RETROGRADE APPROACH FOR CTO

From February 2005 until December 2007, 175 patients were treated with this technique in seven European Centres by highly experienced operators; in 84 (48%) as primary strategy, in 41 (23.5%) immediately after antegrade failure and in 50 (28.5%) as a repeat procedure after previous antegrade failure. The mean occlusion duration was 50.8 months (determined in 32% of patients). The target vessel was: LAD 21%, LCX 6.3%, RCA 71.4%. Epicardial collaterals were accessed in 20.6% and septal in 79.4% of the patients. Overall success rate was 83.4%.
Read more

THE PASSION TRIAL: TWO YEAR FOLLOW-UP

This two year follow-up of the randomised PASSION trail was performed to assess the long-term effects of paclitaxeleluting stents (PES) compared with bare-metal stents (BMS) in patients who had undergone primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). The PASSION trial did not show significant clinical improvement after primary PCI with PES versus BMS in 619 patients with STEMI. There was no significant difference between groups in the incidence of stent thrombosis.
Read more

CUSTOM I FEASIBILITY TRIAL: TWO YEAR FOLLOW-UP

The Custom NX® 36 drug eluting stent (DES) system is designed to treat coronary lesions via in situ stent length customisation. Procedural success was 93%. There were a total of three MACEs reported from enrolment through two year follow-up. In-hospital MACE rate was 2/30, with events in two patients presenting post-procedural non-Q-wave myocardial infarctions without further sequelae. At five months, one patient who had crossed over to PTCA required CABG surgery. One non-cardiac death was reported between one and two year follow-up. There was no in-stent restenosis.
Read more

Ahead of Print

EACTS/ESC POSITION STATEMENT ON TAVI

Among the regular online ahead-of-print publications, the Editorial Board is pleased to highlight the following major paper from Alec Vahanian and Ottavio Alfieri et al. This position statement on transcatheter valve implantation for patients with aortic stenosis is a simultaneous publication in EuroIntervention, the European Heart Journal and the European Journal of Cardiothoracic Surgery. Other Ahead of Print publications can be found here
Read more

EIJ Breaking News

EUROINTERVENTION AT EUROPCR

On Thursday May 15th from 12.00 to 13.30 (Room 122/123 of the CCIB) EuroIntervention's Editor-in-Chief Patrick W. Serruys will chair the first dedicated EuroIntervention symposium at EuroPCR. The speakers have been chosen from papers submitted over the last few weeks and accepted for publication. Each presentation will be followed by an invited commentary.